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Abstract 
Background: Open‑label quetiapine coadministration with SSRI therapy, in a diagnostically mixed sample of comor‑
bid anxiety patients, offered additional anxiolytic benefit. Therefore, we designed the following controlled trial to 
confirm these findings in a comorbid, SSRI‑resistant, panic disorder (PD) patient sample.
Methods: This was a single‑site, double‑blind, placebo‑controlled (PLAC), randomized, parallel group (2 groups), 
8‑week, quetiapine extended release (XR) coadministration trial. SSRI resistance was determined either historically or 
prospectively. Patients were randomized if they remained moderately ill (CGI‑S score ≥ 4). Change in the PDSS scale 
total score was the primary efficacy outcome measure. Responders were identified as those with a ≥50 % decrease 
from their baseline PDSS score. In the early weeks of therapy, XR was flexibly and gradually titrated from 50 to 400 mg/
day.
Results: 43 patients were screened in total, and 26 of these were randomized and evaluable. 21 patients (78 % of 
the randomized group) completed the trial (10 XR; 11 PLAC). The endpoint quetiapine XR mean daily dose ± SD was 
150 ± 106 mg. While, in the sample as a whole, there was improvement in PDSS scores across the 8‑week trial (ANOVA 
main effect of time, F = 10.9, df8,192, p < 0.0001), the treatment × time interaction effect was not statistically significant 
(F = 0.8, df8,192, p = 0.61). There was no between‑group difference in responder frequency at endpoint.
Conclusions: This proof‑of‑concept RCT did not support the efficacy of this treatment strategy for SSRI‑resistant PD. 
Quetiapine XR was generally well‑tolerated. Important limitations were the small sample size, and the relatively low 
average dose of quetiapine XR used.
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Background
While panic disorder (PD) is generally considered a treat-
ment-responsive psychiatric disorder, panic patients with 
agoraphobia and other mood/anxiety disorder comor-
bidities pose a significant therapeutic challenge, and 
have a poorer longer-term prognosis than patients with 
uncomplicated PD [1]. Therefore, clinical studies have 
begun to evaluate the benefit of coadministration proto-
cols that could improve short and longer-term outcomes 
in patients with comorbid panic. In earlier work, we 
observed superior early stabilization of SSRI-treated PD 
patients (30  % also had major depression) with the co-
addition of the benzodiazepine, clonazepam [2]. However, 
maintenance benzodiazepine therapy can be compli-
cated with psychological and physiological dependence. 
Other classes of agents with anxiolytic potential, such 
as the atypical neuroleptics [3, 4], may also be usefully 
combined with SSRIs to facilitate early improvement in 
comorbid PD, and could be more appropriate for main-
tenance treatment. An open-label, 9-week trial (n  =  11 
pts) observed that quetiapine coadministration (mean 
endpoint dose = 180 mg/day) with ongoing SSRI therapy 
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in comorbid anxiety patients can have anxiolytic benefit 
within 1–2 weeks of coadministration therapy [5]. There-
fore, the purpose of the present study was to conduct a 
controlled, proof-of-concept trial to confirm these results 
in a sample of comorbid, SSRI-resistant, PD patients.
Methods
Design
The trial was a double-blind, placebo-controlled, rand-
omized, 8-week, quetiapine XR coadministration trial in 
patients with SSRI-resistant, comorbid PD. In order to 
model clinical practice, study medications were adminis-
tered in a flexible-dosing schedule (see Table 1). Patients 
were randomly assigned either to identically-appearing 
tablets of quetiapine XR (50–400  mg p.o. at night)(XR) 
or placebo (PLAC). For patients receiving adequate 
(8  weeks or longer, in sufficient doses), ongoing SSRI 
therapy at intake, SSRI resistance was ascertained by psy-
chiatrist’s clinical impression of only minimal improve-
ment (a CGI-I level ≥3) [6] with the current SSRI trial 
(20/26 (77 %) of evaluable cases). Patients who were med-
ication-free at intake were initially treated for 8  weeks 
with open-label, sertraline (50–200 mg/day); citalopram 
(20–40 mg/day) or escitalopram (10–20 mg/day). Follow-
ing open-label SSRI treatment, patients that had a <50 % 
decrease from baseline in the PDSS total score after the 
prospective SSRI trial, were classified as “resistant”. The 
study protocol was approved by an IUPUI clinical studies 
IRB committee (study #0703-22), before any patient work 
was conducted. The progress of the study was monitored 
annually by the IRB, and bi-annually by the IU Psychiatry 
Department Adult Studies DSMB committee.
Subjects
We recruited subjects into the IU Anxiety Research 
Clinic located at Indiana University Hospital Adult 
Psychiatry Clinic and Study Center, Indianapolis. We 
employed a mixture of recruitment strategies includ-
ing referrals from local clinicians, flyers displayed in the 
university hospital, on-line bulletins, and paid advertise-
ments in the local newspapers. Participating patients 
received a small stipend for attendance at each study visit 
($15 per visit).
At the initial study visit (Visit 1), and after giving their 
written, informed consent (IUPUI IRB study #0703-22), 
patients underwent a comprehensive medical and psy-
chiatric assessment with the following elements: (1) A 
clinical psychiatric interview, including the Mini Interna-
tional Neuropsychiatric Interview (MINI) [7] (MINI Plus 
version 5.0), to confirm the PD diagnosis with or without 
agoraphobia, (2) psychiatric, medical and surgical his-
tory-taking, (3) prior and concomitant medication and 
procedures (past 30  days), (4) a physical exam includ-
ing vital signs, (5) a 12-lead ECG, (6) clinical chemistry/
hematology including: blood for CBC with differential, 
comprehensive metabolic panel, and thyroid function 
test (T3, T4, TSH), (7) a urine toxicology screen, (8) a 
urine pregnancy test for women of childbearing poten-
tial, and (9) a urinalysis.
The main study inclusion criteria were as follows: 
age  ≥18  years, having a primary, current DSM-IV TR 
diagnosis of PD with or without agoraphobia [8]; and a 
CGI-S score of  ≥4 (moderate illness severity) [6]. Sec-
ondary (non-principal) anxiety and mood disorders were 
allowed. Medical comorbidities were allowed provided 
that medical problems were currently well-controlled. 
Key exclusion criteria included the following items: life-
time psychotic or bipolar diagnoses; current pregnancy 
or lactation; patient currently at significant risk for sui-
cide; a substance abuse disorder within 6  months of 
intake; an unstable medical condition; a history of type I 
or type II diabetes; and a history of neurological disorder 
affecting the CNS.
Prescribing protocol
The dosing range of quetiapine XR we used was 
50–400  mg/day. Our target daily dose for quetiapine 
XR was 200  mg/day. The detailed quetiapine XR dos-
ing guidelines were as follows: 50  mg one tab po at 
HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 
2 tabs at HS × 4 days; at the beginning of week 2, if the 
last dose was tolerated increase to 50 mg 3 tabs at HS × 
3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; 
at the beginning of week 3, if no efficacy and the 200 mg 
dose was well tolerated, increase to one 300  mg tab at 
HS-otherwise remain at 200  mg one tab at HS; at the 
beginning of week 4 if still no improvement, and 300 mg 
was tolerable, increase to 200  mg tablet 2 at HS. From 
the beginning of week 5 to the end of the trial, quetia-
pine XR doses were held. We used quetiapine XR tablets 
Table 1 Baseline patient characteristics (ITT sample; 
mean ± SD values reported)
a Fisher’s exact test. All other baseline comparisons analyzed by independent 
t test





% Female 77 (10/13) 62 (8/13) 0.67a
Age (years) 35.5 ± 9.6 35.5 ± 16.8 0.99
Total PDSS score 14.8 ± 3.6 13.7 ± 3 0.40
CGI‑S score 4.8 ± 0.8 4.4 ± 0.7 0.19
Total HAM‑A score 21.2 ± 6.8 17 ± 5.2 0.09
Total HAM‑D score 14.6 ± 6.2 11.5 ± 5.1 0.18
PSQI sleep hours 6.2 ± 1.3 6.7 ± 1.6 0.39
PSQI sleep quality 2.9 ± 0.6 2.3 ± 0.6 0.02
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and identical-appearing PLAC tablets provided by Astra 
Zeneca (50, 200, and 300  mg designations). The extend 
release (XR) preparation of quetiapine was chosen for its 
potential to limit common side-effects such as sedation. 
Open-label SSRI/SNRI prescriptions were provided by 
the study psychiatrists (WM, YS, AWG). Baseline SSRI/
SNRI doses were held constant throughout the 8-week 
trial. Participants were randomized sequentially by a 
private research pharmacy (Custom Med, Indianapolis). 
The study coordinator (CM)(who was not involved in 
the administration of patient ratings) interacted with the 
research pharmacy to obtain appropriate medication bot-
tles for each patient to be randomized and at each follow-
up visit. Medication adherence was monitored weekly by 
the prescribing psychiatrist by clinical inquiry and assess-
ment of medication bottle returns. Summary records of 
dispensing and returns were maintained in the patient’s 
hard-copy medical chart.
Prohibited medication during the study included the 
following: potent cytochrome P450 inhibitors (includ-
ing but not limited to ketoconazole, itraconazole, flu-
conazole, erythromycin, clarithromycin, troleandomycin, 
indinavir, nelfinavir, ritonavir, fluvoxamine and saqui-
navir), potent cytochrome P450 inducers (including but 
not limited to phenytoin, carbamazepine, barbiturates, 
rifampin, St. John’s Wort, and glucocorticoids), benzodi-
azepines, anticonvulsants (new med starts), other antip-
sychotics, lithium, non-SSRI/SNRI antidepressants, and 
buspirone. Patients were free from standing psychiatric 
medications (except for their ongoing SSRI/SNRI medi-
cine) for 2  weeks prior to the baseline/randomization 
visit. Occasional PRN use (not more than 3 doses/week) 
of a short-acting benzodiazepine in the 2 weeks prior to 
baseline was permitted if clinically necessary.
Clinical measures
Efficacy measures
The primary study objective was to test the hypoth-
esis that SSRI plus quetiapine XR would result in supe-
rior early stabilization of SSRI-resistant, comorbid PD 
patients vs. SSRI/PLAC, as evidenced by more pro-
nounced, clinically significant decreases from baseline 
in total panic disorder severity scale scores (PDSS) [9]. 
Accordingly, weekly PDSS assessments were adminis-
tered by the study psychiatrists. Secondary objectives of 
the study were to explore whether SSRI/quetiapine XR-
treated comorbid PD patients would also have superior 
outcomes vs SSRI/PLAC patients on standard measures 
of depressive symptomatology (HAM-D; baseline, week 
2, week 4, week 8) [10], generalized anxiety symptomatol-
ogy (HAM-A; baseline, week 2, week 4, and week 8) [11], 
sleep hours and quality (PSQI self-report items done 
weekly) [12], and global measures of illness severity and 
improvement (Clinician CGI-S and CGI-I; done weekly) 
[6].
Safety assessments
Study psychiatrists reviewed adverse events/side-effects 
on a weekly basis. They also administered weekly move-
ment side-effect scales, including the Barnes Akathisia 
rating scale [13], and the Simpson-Angus EPS scale 
[14]. Satisfactory physical health was ascertained at the 
screening visit (visit 1) as previously described. In addi-
tion, urine toxicology was repeated at visit 8 to moni-
tor for surreptitious use of benzodiazepines. Vital signs 
including weight were assessed at each visit throughout 
the 9-week study. Blood glucose levels were tested at 
screening, midtrial, and at week 8/endpoint.
Statistical approach
ANOVA with repeated measures analyses were con-
ducted on continuous measures. If these were signifi-
cant, post hoc independent t tests at each time point 
were planned to determine the timing of between-group 
differences. A secondary linear mixed model analy-
sis was also conducted specifically on PDSS data. Non-
parametric (Fisher’s exact test) analyses were performed 
on responder status at the end of weeks 1, 2, 4, and 8/
endpoint (evaluating early, mid, and end-trial treat-
ment effects). A “responder” was defined as a patient 
with ≥50 % improvement from their baseline total PDSS 
score. Both intent-to-treat (ITT) and completer popula-
tions were analyzed. Last-observation-carried-forward 
imputations were used for the ITT patients who with-
drew early. Analyses were performed using SPSS (ver-
sion 21.0). 2-tailed analytic tests were performed with the 
threshold for α set at 0.05. Our initial power calculations, 
generated on PDSS data from a published SSRI/PD coad-
ministration trial [2], assumed a large effect size (d = 1.0) 
at weeks 1 or 2, and a need for 15 patients per treatment 
cell to detect this. Ultimately, only 27/30 planned patients 
were randomized, due to an administrative decision by 
the funding company to terminate the study early during 
the US economic recession.
Results
Evaluable patients
The ITT population characteristics at baseline (n =  26) 
were as follows: female gender 17/26 (65 %) males: 9/26 
(35 %); the mean ± SD age = 36 ± 13 years.; Caucasian 
race  =  88  % (23/26), African American  =  12  % (3/26); 
mean ± SD PDSS total score = 14 ± 3; the mean CGI-S 
score = 4.6 ± 0.8; the mean HAM-D score = 13 ± 6, and 
mean HAM-A score  =  19  ±  6. Thus, the patient sam-
ple had moderate baseline levels of panic symptomatol-
ogy. Table 1 compares the baseline clinical/demographic 
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characteristics of each treatment group. For most base-
line measures, there were no statistically significant 
between-group differences. Comorbid conditions: psy-
chiatric comorbidities in the ITT patients included GAD 
(n = 8), PTSD (n = 3), major depression single or recur-
rent (n = 8), depression NOS (n = 2), dysthymia (n = 1), 
ADD (n = 1), and bulimia in partial remission (n = 1).
Medication doses
The mean  ±  SD endpoint quetiapine XR 
dose =  150 ±  106  mg. Baseline daily SSRI/SNRI doses 
were as follows: sertraline (n  =  7)  =  86  ±  24  mg; 
citalopram (n  =  7)  =  34  ±  10  mg; escitalopram 
(n =  4) =  10 ±  0 mg; fluoxetine (n =  2) =  30 ±  0 mg; 
venlafaxine XR (n  =  1)  =  150  mg; desvenlafax-
ine (n  =  1)  =  100  mg; fluvoxamine (n  =  1)  =  50  mg; 
paroxetine (n  =  2)  =  25  ±  0  mg; and duloxetine 
(n = 1) = 120 mg.
Safety data
Quetiapine XR was generally well-tolerated with the 
exception of three patients who discontinued early due 
to medication-related adverse events (see Fig.  1). Som-
nolence/sedation was the most commonly reported 
treatment-emergent adverse event but was usually mild 
(Table  2); there was no statistical XR/PLAC group dif-
ference on frequency of this or other commonly experi-
enced AEs. Vital signs (BP, HR) remained stable during 
the 8-week trial (data not shown). A slight weight gain 
was observed in both treatment groups: quetiapine XR 
(mean ±  SD weight; 181 ±  39 to 186 ±  41  lbs at end-
point); PLAC patients (175 ± 50 to 177 ± 48 lbs at end-
point). However, a between-group comparison of weight 
gains revealed that they were not significantly different 
(independent t test t  =  1.73, df 1, p  =  0.33) (ITT pts). 
Blood glucose levels remained within the normal range 
at screening, midpoint, and endpoint. Urine toxicologies 
were negative at screening and endpoint. Based on clini-
cal observations, including minimal score changes on 
the movement symptom scales, neither extrapyramidal 
side-effects nor akathisia were problematic. For example, 
mean Simpson Angus total score changes from baseline 
to endpoint were similar in quetiapine XR and PLAC 
patients (−0.6  ±  1.0 vs −0.2  ±  0.8; two-tailed t  =  1.4, 
df = 24, p = 0.19). Also, quetiapine XR vs PLAC patients’ 
mean Barnes Akathisia total score changes from baseline 
to endpoint were not statistically different (−1.6 ± 1.7 vs 
−0.5 ± 1.5; t = 1.7, df = 24, p = 0.09).
Efficacy data
PDSS data
The primary efficacy analysis was a repeated meas-
ures ANOVA of PDSS total scores data, performed 
on ITT patients (see Fig.  2 for plot of PDSS scores by 
time). There was a highly significant main effect of time 
(F  =  10.9, df8,192, p  <  0.0001), consistent with clini-
cal improvement in the patient sample over the 8-week 
trial period. However, the treatment × time interaction 
Fig. 1 Patient flow summary (randomization: XR n = 14, PLAC 
n = 13)
Table 2 Common treatment-emergent adverse events 
(most to least prevalent)
No significant differences between groups were detected at the p < 0.05 level 
(Fisher’s exact test)
a 3 patients in the XR group discontinued due to side-effects (somnolence or 
derealization). There were no serious AEs (ones requiring ER or inpatient care)




Somnolencea 10 (77 %) 5 (38 %)
Anxiety 4 (31 %) 0 (0 %)
Constipation 3 (23 %) 1 (8 %)
Dry mouth 3 (23 %) 0 (0 %)
Dizziness 2 (15 %) 3 (23 %)
Restlessness 2 (15 %) 4 (31 %)
Derealizationa 2 (15 %) 0 (0 %)
Insomnia 1 (8 %) 3 (23 %)
Increased appetite 1 (8 %) 2 (15 %)
Leg pain 1 (8 %) 1 (8 %)
Weight loss 1 (8 %) 0 (0 %)
Shakiness 1 (8 %) 0 (0 %)
Muscle aches 0 (0 %) 2 (15 %)
Weight gain 0 (0 %) 1 (8 %)
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term was not significant [F = 0.8, df8,192, p = 0.61; end-
point mean PDSS difference score = +1.4 (95 % CI −3.1 
to 5.9)], indicating that the XR group was not superior to 
PLAC on this important outcome. Rerunning the analysis 
using baseline HAM-A scores as a covariate (since there 
was a trend baseline, between-group difference), did not 
alter the findings appreciably. A linear mixed models 
analysis of PDSS scores also failed to detect a drug/pla-
cebo difference [fixed effect (active vs placebo), F = 0.15; 
df1,23.9, p = 0.7]. ANOVA of PDSS scores of the completer 
population, as expected, revealed a highly significant 
main effect of time (F = 12.1, df 8,152, p < 0.0001), but a 
non-significant treatment × time interaction (F =  0.63, 
df8,152, p  =  0.75). Furthermore, an ANOVA of the sub-
group of patients whose SSRI resistance was historically 
determined (n =  20), also produced similar results. An 
additional ITT analysis was conducted on item #1 of the 
PDSS scale (which assesses panic attack frequency/inten-
sity). Again, there was a highly significant main effect of 
time for this measure (F = 7.2, df8,184, p < 0.0001), but a 
non-significant treatment × time interaction (F =  0.51, 
df8,184, p =  0.85). As mentioned earlier, 11/26 evaluable 
patients had a comorbid depressive disorder. Therefore, 
we conducted an exploratory ANOVA to examine the 
potential impact of depression diagnosis on PDSS total 
scores over time. The main effect of time was highly sig-
nificant (F =  10, df8,192, p  <  0.0001), and there was also 
a statistically significant depression x time interaction 
effect (F = 2.4, df8,192, p < 0.02), indicating that patients 
with depression comorbidity (receiving quetiapine or 
placebo) tended to improve less on the PDSS scale vs 
non-depressed patients. Notably, though, analyses of the 
subgroups of non-depressed PD (n = 15) and depressed 
PD patients (n = 11), did not reveal significant treatment 
x time interaction effects (F = 0.66, df8,104, p = 0.73, and 
F = 0.81, df8,72, p = 0.6, respectively). Thus, neither pres-
ence nor absence of comorbid depression were associated 
with a tendency to have an improved anti-panic response 
to quetiapine XR coadministration.
In addition, non-parametric analyses (Fisher’s exact 
tests) were performed on clinical responder data (ITT 
sample) at weeks 1, 2, 4, and 8/endpoint, and revealed 
similar response levels for the 2 treatment groups. At 
week 1, 1/13 (7  %) of XR patients were classified as 
responders vs 3/13 (23  %) PLAC patients (p  =  0.59). 
After week 2, 2/13 (15  %) quetiapine XR patients were 
responders vs 3/13 (23  %) PLAC-treated patients 
(p = 1.00). At the end of week 4 (midpoint of the trial), 
7/13 (54 %) quetiapine XR cases were responders vs 4/13 
(31 %) for PLAC (p = 0.43). At endpoint, 6/13 (46 %) of 
quetiapine XR patients met responder criteria vs 5/13 
(38 %) of PLAC patients (p = 1.00). Responder analyses 
performed on the completer patient population produced 
similar results. We also conducted an analysis on “remit-
ters” at endpoint (patients with a PDSS total score ≤4), 
and found no between-group difference on this measure 
(4/13 XR patients vs 3/13 PLAC patients, p = 1.00).
Secondary efficacy measures (CGI‑S, CGI‑I, HAM‑D, HAM‑A, 
PSQI)
Repeated measures ANOVA analyses were also con-
ducted on each of the secondary efficacy measures, with 
a similar pattern of findings to the primary efficacy anal-
ysis (i.e. similar levels of clinical improvement in both 
groups over the trial period). There was a highly signifi-
cant main effect of time for the clinician CGI-S measure 
Fig. 2 Efficacy data. Mean ± SD PDSS total scores (0–28) (ITT data set; n = 26)
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(F = 17.8, df8,192, p < 0.0001), but a non-significant treat-
ment × time interaction (F = 0.72, df8,192, p = 0.67). Like-
wise for the clinician CGI-I outcome measure, there was 
a highly significant main effect of time (F =  6.6, df7,168, 
p < 0.0001), but a non-significant treatment x time inter-
action term (F  =  0.6, df7,168, p  =  0.73). HAM-A scores 
improved over time (main effect of time; F  =  14.9, 
df3,72, p < 0.0001), but there was no evidence of superior 
improvement in the quetiapine XR group (treatment 
× time interaction F =  0.89, df3,72, p =  0.45). Similarly, 
HAM-D scores improved over time (F  =  15.4, df3,72, 
p  <  0.0001), but with no significant treatment x time 
interaction effect (F  =  1.9, df3,72 p  =  0.13). Regarding 
sleep hours (a PQSI self-report item), there was both a 
trend level of statistical significance for the ANOVA 
main effect of time (F = 1.94, df8,192, p < 0.06), and for the 
treatment x time interaction (F = 1.85, df8,192, p < 0.07). 
The latter trend finding was related to early improvement 
(over the first 4 weeks) in sleep time in the quetiapine XR 
group. For the sleep quality item of the PSQI, there was a 
significant main effect of time (F = 2.02, df8,192, p < 0.05), 
but a non-significant treatment x time effect (F  =  1.1, 
df8,192, p = 0.36).
Discussion
In this trial, we did not observe efficacy of the quetiapine 
XR augmentation strategy on both primary and second-
ary efficacy measures, in contrast to the positive findings 
of the case-report/open-label trial literature [4, 5]. There 
was a trend toward improvement in sleep time in quetia-
pine XR group, consistent with sleep benefits reported 
in several recent quetiapine trials [15, 16]. Comorbid 
depression was associated with relative resistance to 
treatment (XR or PLAC). Our results supported the 
patient acceptability and safety of flexible-dose quetia-
pine XR augmentation for resistant PD. Though sedation/
somnolence was commonly reported, other concerning 
AEs, such as metabolic or extrapyramidal side-effects, 
were not observed over the relatively brief time-frame of 
the trial.
This investigation was the first RCT, which we are 
aware of, that has studied atypical neuroleptic augmenta-
tion of SSRI treatment in patients with a primary diag-
nosis of PD. While there has been a recent trend towards 
“off-label” prescribing of atypicals for anxiety disorders 
such as PD [17], there have been few controlled studies 
to inform this practice. To date, the best evidence sup-
porting atypical use for anxiety syndromes is for gener-
alized anxiety disorder [18–20] and OCD [21]. Of note, 
however, one GAD trial of atypical augmentation of 
SSRI therapy, was negative. [22] However, with regard 
to PD, RCTs studying the antipanic effects of atypical 
neuroleptics (quetiapine, risperidone, ziprasidone) have 
primarily evaluated bipolar patients with comorbid panic 
symptoms [23–25]. Of these trials, only the quetiapine 
(monotherapy) one was positive.
The strengths of this proof-of-concept trial included 
the significance for clinical practice (addressing a 
common clinical dilemma of what to do when SSRI-
resistance occurs), the controlled design, the use of psy-
chiatrists to monitor patient safety and administer key 
efficacy ratings such as the PDSS and CGI ratings, the 
careful medical screening and patient selection, and 
the flexible treatment protocol mirroring clinical prac-
tice. Limitations of the trial included the small sample 
size and being underpowered to detect small-moderate 
effects. To be powered to detect a modest effect, simi-
lar to the mid-trial responder results, would have 
required approximately 50 patients per treatment con-
dition. Additional design limitations included the mixed 
method of determining SSRI resistance, possible under-
dosing of XR in the first 4  weeks (our mean endpoint 
XR dose = 150 mg (vs 186 mg in the positive quetiapine 
trial of Sheehan et al. [24]), and the lack of independent 
evaluators/raters. Relatively low-dosing of quetiapine 
XR, however, may be preferable in PD and other anxiety 
spectrum disorders, given that, at the 150 mg/day dose 
level, optimal anxiolytic effects have been observed in 
GAD patients [18]. Furthermore, in laboratory models, 
the putative anxiolytic action of atypical antipsychotic 
agents (prefrontal cortical 5-HT2A/C receptor antago-
nism) appears to be optimal at lower dose levels [26, 27]. 
In addition, though the placebo augmentation response 
was significant, it is important to note that all subjects 
were on an active anti-panic regimen (SSRI/SNRI treat-
ment), and a prolonged trial of these medications may 
well have resulted in a response 8 weeks later. The ben-
efits seen with placebo treatment was also not incon-
sistent with what is generally reported in panic clinical 
trials [28, 29]. However, a less frequent visit schedule 
may have helped to limit this further, thereby improv-
ing signal detection. Other design features, such as a 
placebo run-in period, could also have limited placebo 
response. Of note, on inspection (Fig. 2) during most of 
the trial there was increased variability of PDSS scores 
in the XR vs PLAC-treated patients, possibly reflecting 
increased anxiety of some patients in response to XR 
side-effects, thereby impacting signal detection. Also, 
other patient-specific factors, such as the use of mul-
tiple antidepressant agents at varying doses, and the 
presence of a range of psychiatric comorbidities may 
have generally contributed to the variability of our effi-
cacy data, and affected our ability to detect a treatment 
signal.
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Conclusions
This was clearly a negative clinical trial with respect 
to large treatment effects of quetiapine XR for SSRI-
resistant PD. Low doses of quetiapine XR appeared 
to be well-tolerated in PD patients, noteworthy in a 
patient population that is generally fearful of medication 
changes and side-effects. Metabolic and extrapyramidal 
side-effects were minimal. Sleep benefits are a potential 
advantage of this augmentation strategy, which merit 
additional study.
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